Primary objectives:
- To compare Disease-Free Survival (DFS) of an adjuvant treatment with docetaxel given
either sequentially or in combination with doxorubicin and followed by CMF to
doxorubicin alone or in combination with cyclophosphamide and followed by CMF in
operable breast cancer patients with positive axillary lymph nodes.
Secondary objectives:
- To compare DFS of an adjuvant treatment with doxorubicin followed by docetaxel followed
by CMF to doxorubicin followed by CMF in operable breast cancer patients with positive
axillary lymph nodes
- To compare DFS of an adjuvant treatment with docetaxel in combination with doxorubicin
followed by CMF to doxorubicin in combination with cyclophosphamide followed by CMF in
operable breast cancer patients with positive axillary lymph nodes
- To compare DFS of an adjuvant treatment with doxorubicin followed by docetaxel followed
by CMF to doxorubicin in combination with docetaxel followed by CMF in operable breast
cancer patients with positive axillary lymph nodes, (sequential mono-chemotherapy versus
polychemotherapy).
- To compare overall survival of treatment arms.
- To compare toxicity of treatment arms.
- To evaluate pathologic and molecular markers for predicting efficacy.
- Socioeconomic data will be collected in order to be able to perform a socioeconomic
analysis by country, when needed.